Week In Review: Three $300 Million Deals For China Biopharma
November 07, 2020 at 12:31 PM EST
China Grand Pharma announced a $340 million agreement to develop and commercialize Telix Pharma's molecularly-targeted radiation products in China. China Grand Pharma will make a $25 million upfront payment and invest $25 million in Telix.
